Humoral Responses to SARS-CoV-2 Infection and mRNA Vaccination Open Access
Mantus, Grace (Spring 2022)
Published
Abstract
First detected in 2019, SARS-CoV-2 remains a global pandemic with over 430 million individuals infected to date. Significant homology between SARS-CoV-2 and -1 allowed the rapid identification of the spike (S) protein, specifically the receptor binding domain (RBD), as a critical target for neutralizing antibodies. Given the rapid spread of the virus, characterizing potentially protective aspects of the immune response to infection was urgent. In a cohort of individuals hospitalized with severe COVID-19, we observed robust B cell responses, detecting expanded plasmablasts, activated RBD-specific memory B cells, and elevated titers of RBD- and S-specific antibodies. Depletion of RBD-specific antibodies from serum significantly reduced neutralizing activity in the majority of individuals. However, some donors retained significant residual neutralization activity, suggesting a potentially protective antibody subset targeting non-RBD epitopes. This study demonstrated that SARS-CoV-2 infection induces a robust humoral response and that RBD-specific antibodies are critical for circulating viral neutralization in infected individuals.
Soon after the emergence of SARS-CoV-2, hundreds of vaccines went into pre-clinical and clinical testing in an effort to combat the growing global pandemic. By the end of 2020, the U.S. had approved two mRNA-based vaccines from Moderna and Pfizer. While initial reports of efficacy were high for both vaccines, the emergence of several SARS-CoV-2 variants raised questions about the breadth and durability of the vaccine-induced humoral response. To this end, we analyzed the humoral response to either Moderna or Pfizer mRNA vaccination in a longitudinal cohort of naïve and recovered individuals. We found that, while vaccination induced SARS-CoV-2 specific humoral immunity in both groups, the antibody response was both more robust and durable in recovered individuals than naïve individuals and that vaccine responses positively correlated with initial responses to infection in recovered individuals. Despite the similarity of the mRNA vaccines, Moderna-vaccinated naïve individuals demonstrated a less reliance on RBD-specific antibodies for neutralization than Pfizer vaccinees. Taken together, these studies illustrate that both infection and vaccination against SARS-CoV-2 can elicit potent and protective humoral responses.
Table of Contents
CHAPTER 1: INTRODUCTION................................................................................................ 1
B CELLS IN VIRAL INFECTIONS........................................................................................... 2
B Cell Activation..................................................................................................................... 2
Extrafollicular Responses........................................................................................................ 3
Germinal Center Responses.................................................................................................... 5
Antibody Effector Functions................................................................................................... 7
SARS-CoV-2.............................................................................................................................. 9
SARS-CoV-2: Relationship to other human b-coronaviruses................................................ 9
Viral Structure and Replication............................................................................................. 11
Disease Pathology................................................................................................................. 14
HUMORAL RESPONSES TO SARS-CoV-2.......................................................................... 17
Lessons from Human Coronaviruses.................................................................................... 17
Antibody Responses to SARS-CoV-2 Infection................................................................... 20
B Cell Responses to SARS-CoV-2 Infection........................................................................ 25
COVID-19: TREATMENT AND PREVENTION................................................................... 29
Current SARS-CoV-2 Treatments........................................................................................ 29
SARS-CoV-2 Vaccination Strategies.................................................................................... 30
The Success of SARS-CoV-2 mRNA vaccines.................................................................... 32
THE EVOLUTION OF SARS-CoV-2...................................................................................... 35
Endemic Coronavirus Evolution: Evidence & Mechanisms................................................. 35
SARS-CoV-2: The Emergence of Viral Variants................................................................. 36
SUMMARY.............................................................................................................................. 38
CHAPTER 2: EVALUATION OF CELLULAR AND SEROLOGICAL RESPONSES TO ACUTE SARS-COV-2 INFECTION DEMONSTRATE THE FUNCTIONAL IMPORTANCE OF THE RECEPTOR BINDING DOMAIN 41
Abstract.................................................................................................................................. 42
Introduction........................................................................................................................... 43
Methods................................................................................................................................... 46
Results..................................................................................................................................... 52
Discussion................................................................................................................................ 59
Acknowledgements & Funding Information.................................................................... 64
Author Contributions.......................................................................................................... 64
Declaration of Interests..................................................................................................... 65
Figure 1. Acute COVID-19 patients exhibit loss of circulating memory B cells and expansion of plasmablasts. 66
Figure 2. RBD-specific memory B cells expand rapidly and exhibit high levels of activation in COVID-19 patients. 68
Figure 3. RBD-binding fraction of patient serum antibody strongly correlates with neutralization capacity 69
Figure 4. SARS-CoV-2 viral neutralization activity is mediated by RBD specific antibody in a majority of COVID-19 patients.................................................................................................................................................... 70
Supplemental Figure 1. CD4+ and CD8+ T cells decreased in COVID-19 patients..... 71
Supplemental Figure 2. RBD-specific MBCs are found in both the CD27+ and CD27- subsets 72
Supplemental Figure 3. RBD-specific IgG titers correlate with time from infection 73
Supplementary Table 1. Clinical & Serological Data Summary................................. 74
CHAPTER 3: PRE-EXISTING SARS-COV-2 IMMUNITY INFLUENCES POTENCY, BREADTH, AND DURABILITY OF THE HUMORAL RESPONSE TO SARS-COV-2 VACCINATION.............................................. 75
Summary.................................................................................................................................. 76
Introduction........................................................................................................................... 77
Methods................................................................................................................................... 79
Results..................................................................................................................................... 85
Discussion................................................................................................................................ 98
Acknowledgements............................................................................................................. 105
Author Contributions........................................................................................................ 106
Declaration of Interests................................................................................................... 106
Figure 1. RBD-specific memory B cells expand in naïve and recovered subjects following mRNA vaccination. 108
Figure 2. RBD-specific memory B cells upregulate CD71 following infection and vaccination. 109
Figure 3. Plasmablast responses in naïve and recovered individuals post SARS-CoV-2 mRNA vaccination. 111
Figure 4. Recovered individuals generate faster and more robust antibody responses to mRNA vaccination against SARS-CoV-2 than naïve individuals........................................................................................................ 113
Figure 5. Antigen-specific MBC and serological responses to SARS-CoV-2 infection correlate with responses to mRNA vaccination........................................................................................................................... 115
Figure 6. Naïve Moderna-vaccinated individuals retain greater neutralizing capacity after depletion of RBD-specific fraction of plasma............................................................................................................................... 117
Figure 7. Naïve vaccinees exhibit a faster decline in Spike, RBD, and NTD-specific IgG six months after vaccination than previously SARS-CoV-2 infected vaccinees................................................................... 118
Supplemental Table 1. Demographic information for Emory University SARS-CoV-2 immune surveillance and vaccination studies.................................................................................................................................... 119
Supplemental Figure 2. MSD-ELICA binding titers for SARS-CoV-2 isotypes and related antigens. 120
Supplemental Figure 3. MSD-ELICA titers to variant RBD and neutralization by vaccine brand 121
Supplemental Figure 4. RBD-specific antibody depletion by isotype and correlation of anti-Spike titers to RBD-specific neutralization..................................................................................................................... 122
Supplemental Table 1. Demographic information for Emory University SARS-CoV-2 immune surveillance and vaccination studies.................................................................................................................................... 123
Supplemental Table 2: Statistics for RBD-specific MBC. Median, mean, standard deviation, and n are listed for data reported in Figure 1.................................................................................................................................. 124
Supplemental Table 3. Statistics for total and RBD-specific plasmablasts. Median, mean, standard deviation, and n are listed for data reported in Figure 3............................................................................................ 125
Supplemental Table 4. Statistics for anti-spike antibody across seven timepoints in cohort 126
Supplemental Table 5. Statistics for anti-RBD antibody across seven timepoints in cohort 127
Supplemental Table 6. Statistics for anti-NTD antibody across seven timepoints in cohort 128
Supplemental Table 7. Statistics for anti-spike, -RBD, and -NTD antibody across seven timepoints in cohort grouped by past infection status.................................................................................................................... 129
CHAPTER 4.............................................................................................................................. 130
DISCUSSION............................................................................................................................. 130
CONCLUSION....................................................................................................................... 131
FUTURE CONSIDERATIONS.............................................................................................. 133
Autoimmunity and COVID-19............................................................................................ 133
Influences on B Cell Repertoire.......................................................................................... 135
OUR PANDEMIC FUTURE................................................................................................... 139
Emergence & Escape of Omicron....................................................................................... 139
“Future Vaccines” : Combatting Variants Before They Arise............................................ 141
SUMMARY............................................................................................................................ 144
Figure 1. Majority of plasmablasts induced in severe COVID-19 are of unknown antigen-specificity. 146
Figure 2. Antibody repertoires between recovered and vaccinated individuals are similar and share several public antibody clones..................................................................................................................................... 148
REFERENCES.......................................................................................................................... 149
About this Dissertation
School | |
---|---|
Department | |
Subfield / Discipline | |
Degree | |
Submission | |
Language |
|
Research Field | |
Keyword | |
Committee Chair / Thesis Advisor | |
Committee Members |
Primary PDF
Thumbnail | Title | Date Uploaded | Actions |
---|---|---|---|
|
Humoral Responses to SARS-CoV-2 Infection and mRNA Vaccination () | 2022-03-26 10:43:37 -0400 |
|
Supplemental Files
Thumbnail | Title | Date Uploaded | Actions |
---|